Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Both human epidermal growth factor receptor 2 (HER-2/neu) and VEGF overexpression correlate with aggressive phenotypes and decreased survival among breast cancer patients. Concordantly, the combination of trastuzumab (anti-HER2) with bevacizumab (anti-VEGF) has shown promising results in preclinical xenograft studies and in clinical trials. However, despite the known antiangiogenic mechanism of anti-VEGF antibodies, relatively little is known about their effects on the pharmacokinetics and tissue distribution of other antibodies. This study aimed to measure the disposition properties, with a particular emphasis on tumor uptake, of trastuzumab in the presence or absence of anti-VEGF. Radiolabeled trastuzumab was administered alone or in combination with an anti-VEGF antibody to mice bearing HER2-expressing KPL-4 breast cancer xenografts. Biodistribution, autoradiography, and single-photon emission computed tomography–X-ray computed tomography imaging all showed that anti-VEGF administration reduced accumulation of trastuzumab in tumors despite comparable blood exposures and similar distributions in most other tissues. A similar trend was also observed for an isotype-matched IgG with no affinity for HER2, showing reduced vascular permeability to macromolecules. Reduced tumor blood flow (P < 0.05) was observed following anti-VEGF treatment, with no significant differences in the other physiologic parameters measured despite immunohistochemical evidence of reduced vascular density. In conclusion, anti-VEGF preadministration decreased tumor uptake of trastuzumab, and this phenomenon was mechanistically attributed to reduced vascular permeability and blood perfusion. These findings may ultimately help inform dosing strategies to achieve improved clinical outcomes. Mol Cancer Ther; 11(3); 752–62. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“Downregulation of VEGF signaling in tumors is pursuedas anopportunity to restore vasculature to normalcy, a state requiring both spatial and temporal control of VEGF levels (27).”
BackgroundVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Finkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0448 · Cited by 125
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Indeed, efficacious doses of anti-VEGF agents that are commonly used in preclinical (Arjaans et al., 2013; Pastuskovas et al., 2012) or clinical (Van der Veldt et al., 2012; Zissen et al., 2011) studies have been unexpectedly reported to result in a sustained reduction in tumor uptake of cytotoxic…”
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Metadata
- Authors
- Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., Cain, G., Van Hoy, M., Majidy, N., Bheddah, S., dela Cruz Chuh, J., Kozak, K. R., Lewin-Koh, N., Nauka, P., Bumbaca, D., Sliwkowski, M., Tibbitts, J., Theil, F.-P., Fielder, P. J., Khawli, L. A., & Boswell, C. A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2012-03-01
- Volume
- 11
- Issue
- 3
- Pages
- 752-762
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2112154408
- Cited by
- 103
- References
- 4
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0742-t
- The paper
- Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., Cain, G., Van Hoy, M., Majidy, N., Bheddah, S., dela Cruz Chuh, J., Kozak, K. R., Lewin-Koh, N., Nauka, P., Bumbaca, D., . . . Boswell, C. A. (2012). Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0742-t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.